Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Marc LABROLI and Kartik KEERTIKAR. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. 2007.

Basic information

Original name

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Name in Czech

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Authors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Marc LABROLI and Kartik KEERTIKAR

Edition

Number: US 2007/00772881 A1, Publisher: United States Patent and Trademark Office, Place of publication: USA, Owner's name: Schering-Plough, 2007

---

Other information

Language

English

Type of outcome

Patent

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Science

Keywords (in Czech)

pyrazolopyrimidine; cyclin dependent kinase; inhibitor

Keywords in English

pyrazolopyrimidine; cyclin dependent kinase; inhibitor

Tags

Cyclin dependent kinase, inhibitor, pyrazolopyrimidine

---

Abstract

V originále

Title compds. I [R = H, alkyl, alkenyl, etc.; R2 = H, CF3, alkyl, heterocyclyl, etc.; R3 = H, halo, OH, SH, alkyl, etc.; R4 = H, halo or alkyl], and their pharmaceutically acceptable salts, are prepd. and disclosed as inhibitors of cyclin dependent kinases (CDKs). Thus, e.g., II was prepd. by amination of III (prepn. given) followed by deprotection. Methods for in vitro kinase assays are described, e.g., II was found to possess an IC50 value of 10 (.mu.M). Further disclosed are pharmaceutical compns. contg. one or more of I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns.

In Czech

viz Anotace